- Report
- November 2021
- 1165 Pages
Global
From €5461EUR$6,000USD£4,638GBP
- Report
- November 2021
- 1184 Pages
Global
From €5461EUR$6,000USD£4,638GBP
- Report
- July 2024
- 280 Pages
Global
From €1692EUR$1,859USD£1,437GBP
€2416EUR$2,655USD£2,052GBP
- Report
- July 2022
- 315 Pages
Global
From €2447EUR$2,688USD£2,078GBP
€3495EUR$3,840USD£2,969GBP
- Report
- July 2022
- 234 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
- Report
- May 2022
- 205 Pages
Global
From €2202EUR$2,419USD£1,870GBP
€3146EUR$3,456USD£2,672GBP
- Report
- December 2021
- 170 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Book
- May 2024
- 464 Pages
- Book
- March 2024
- 544 Pages
- Book
- November 2023
- 304 Pages
- Book
- March 2022
- 896 Pages
- Book
- April 2021
- 288 Pages
- Book
- April 2018
- 432 Pages
- Book
- January 2012
- 660 Pages
- Book
- March 2014
- 844 Pages

RNA interference (RNAi) is a biotechnological process that uses small pieces of double-stranded RNA (dsRNA) to inhibit gene expression. It is a powerful tool for studying gene function and has been used to develop treatments for a variety of diseases. RNAi has been used to target and silence specific genes, allowing researchers to study the effects of gene silencing on cell function. It has also been used to develop treatments for cancer, viral infections, and other diseases.
RNAi technology has been used to develop a variety of therapeutics, including small interfering RNAs (siRNAs), microRNAs (miRNAs), and antisense oligonucleotides (ASOs). siRNAs are short pieces of dsRNA that can be used to target and silence specific genes. miRNAs are small pieces of single-stranded RNA that can regulate gene expression. ASOs are short pieces of DNA that can be used to target and silence specific genes.
The RNAi market is a rapidly growing segment of the biotechnology industry. Companies in the market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioNTech, Editas Medicine, and Moderna Therapeutics. These companies are developing a variety of RNAi-based therapeutics for a range of diseases. Show Less Read more